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In this study, we investigated the presence of E6/E7 transcripts of seven common high-risk human papillomavirus (HPV) types in 190
cervical biopsies. The RNA-based real-time nucleic acid sequence-based amplification assay (NASBA) and type-specific PCR, both
detecting HPV 16, 18, 31, 33, 45, 52, and 58, as well as consensus PCR, were performed on all 190 biopsies. High accordance
between type-specific and consensus PCR confirms that the HPV types included in this study are the most common types present in
cervical dysplasia. Furthermore, we see a clear increase in the incidence of HPV, both DNA and RNA, along with the histological
severity of dysplasia. HPV RNA was detected in all but two PCR-positive cases, confirming that the virus exerts E6/E7 mRNA
expression in cases of high-grade dysplasia. Out of 19 women given a normal or borderline diagnosis at conisation, only four were
found HPV positive, which may suggest that unnecessary conisations can possibly be reduced by introducing HPV testing into the
preoperative routine assessment.
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Human papillomavirus (HPV) infections are associated with the
development of cervical neoplasia and are a necessary factor in the
aetiology of cervical carcinoma (Walboomers et al, 1999; Bosch
et al, 2002; zur Hausen, 2002). The most frequent HPV types found
in high-grade cervical intraepithelial dysplasia (CIN II/III) and in
cervical carcinomas are HPV 16, 18, 31, 33, and 45, which are often
referred to as high-risk HPV or cancer-associated HPV types.
However, the association between a positive HPV DNA test and the
risk of subsequent development of dysplasia is partly unknown;
the presence of HPV DNA does not necessarily indicate a risk for
developing a more severe lesion. In fact, HPV is a very common
virus among sexually active women and most infections are
transient and asymptomatic (zur Hausen, 1991; Ho et al, 1998;
Moscicki et al, 1998). Only very few infections cause morphologic
changes in the epithelium and only a small percent of these will
eventually develop cervical cancer (Bosch et al, 1995). On the other
hand, several studies have shown that in cervical carcinogenesis,
the expression of HPV E6 and E7 ORF is required for cell
transformation and immortalisation (zur Hausen, 1988; Munger
et al, 1989; Stoler et al, 1992). Consequently, persistent expression
of these oncogenes may serve as an indicator of progression to CIN
and invasive cancer (Sotlar et al, 1998), and detection of E6 and E7
mRNA transcripts may therefore be of higher prognostic value
than the detection of HPV DNA. Moreover, new methods for
preservation of RNA in cells have made gene expression analysis
more feasible.
In this study, we investigated the presence of high-risk HPV
E6/E7 transcripts in cervical biopsies from patients undergoing
conisation. The analysis was performed on a biopsy taken from
the ectocervix/transformation zone at the time of conisation, and
the pathological diagnosis of this particular biopsy was not
always representative for the existing lesion that was later
revealed in the cone. This strategy gave us access to a uniformly
preserved material with varying degrees of squamous cell
dysplasia, yet from cones that in most cases harboured a CIN III
lesion. For RNA detection, the RNA-based real-time nucleic acid
sequence-based amplification assay (NASBA) was used, focusing
on the reportedly most common oncogenic HPV types 16, 18, 31,
33, 45, 52, and 58 (Walboomers et al, 1999; Munoz et al, 2003).
Results were compared with cytologic and histopathologic
findings, and HPV DNA status as assessed by consensus and
type-specific PCR.
MATERIALS AND METHODS
Cell culture
The cervical carcinoma cell lines SiHa (squamous cell carcinoma),
CaSki (squamous cell carcinoma), and HeLa (adenocarcinoma),
used as positive controls, were obtained from the American Type
Culture Collection, USA. The SiHa and HeLa cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM),
CaSki cells in RPMI medium, supplemented with 10% fetal bovine
serum (FBS), 2mML -glutamine, and 25mgml
 1 gentamicin. The
cells were incubated at 371C in a 5% CO2 atmosphere. The cells
were harvested directly in lysis buffer (bioMe ´rieux, the Nether-
lands, containing 5 M guanidine thiocyanate).
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The study was performed on 190 consecutive biopsies, taken from
190 women admitted to Østfold County Hospital for treatment of
CIN during the period October 1999 to October 2001. The mean
age at diagnosis was 37.4 years (range 22–74 years). Biopsies were
frozen at  701C immediately after collection. All women were
subjected to subsequent conisation.
Cytological and histological examination of samples
Initially, routine cytological grading was performed according to
local routine guidelines. No review cytology was performed. After a
high-grade cytology report, or an equivocal cytological smear, the
patients were referred to colposcopy and biopsy (Østfold County
Hospital). Iodine painting of the portio was used as a means of
visualising dysplasia. Multiple biopsies were taken from the
external os and from any colposcopically pathological lesion. In
addition, the cervical canal was scraped. If these biopsies (Biopsy
1/Histology 1, Table 1) confirmed a high-grade lesion (CIN II/III),
the patient was again admitted to hospital, this time for conisation.
In some cases, the patients were referred to conisation on the basis
of an unclear diagnosis or a long-lasting persistent CIN I lesion.
For these cases, only a diagnostic cone was taken, as small as
possible. If the woman did not plan for future pregnancy, a
combined diagnostic and therapeutic conisation was performed.
Before conisation, but after local anaesthesia was applied, a single
biopsy (Biopsy 2/Histology 2b, Table 1) was taken from the
ectocervix. This biopsy (2 2mm) was frozen within 2min at
 701C. Biopsy 2 was split in two when frozen, and half was used
for DNA/RNA extraction. The other half was fixed in 10% buffered
formaldehyde and processed for histopathological examination.
Some lesions were not correctly oriented in the paraffin block and
had to be reoriented or serial sectioned in order to show the
relevant surface epithelium. Consequently, it cannot be guaranteed
that the histopathological diagnosis reflect the actual condition of
the tissue used for extraction. Finally, the cone specimen was
evaluated by a histopathologist, who subsequently confirmed or
disproved the presence and severity of dysplasia (Histology 3,
Table 1).
Extraction of nucleic acids
Nucleic acids were isolated using the automated NucliSens
Extractor (bioMe ´rieux, the Netherlands) as previously described
(Boom et al, 1990). Briefly, the material was divided into smaller
pieces while kept on dry ice ( 801C) and subsequently transferred
to 1ml of lysis buffer (bioMe ´rieux) followed by 20s of
homogenisation using disposable pestles, after which 100mlo f
the sample was further diluted 10-fold in lysis buffer. A 100ml
volume was then used for the DNA/RNA extraction, which resulted
in a final elution volume of  40ml. Extracts were stored at  701C.
NASBA protocol: amplification and detection of HPV RNA
Human papillomavirus RNA was detected by real-time NASBA
(Compton, 1991; Chan and Fox, 1999; Deiman et al, 2002).
Reagents were obtained from NorChip (Klokkarstua, Norway), as
they are presented in the commercially available PreTect HPV-
Proofer kit. Briefly, NASBA is based on isothermal RNA
amplification, accomplished by the simultaneous enzymatic
activity of avian myeloblastosis virus (AMV) reverse transcriptase,
T7 RNA polymerase, and RNase H (Compton, 1991). For detection
we used primers and molecular beacon (MB) probes directed
against E6/E7 mRNA for HPV types 16, 18, 31, 33, 45, 52, and 58
(NorChip, Klokkarstua, Norway). Final concentration of MBs used
in the reaction was 2.5mM. The NASBA amplification was carried
out in a volume of 20mla t4 1 1C for 2h. A 5ml volume of nucleic
acids, diluted five times after extraction, was included in the
reaction. As performance control, to avoid false negatives due to
degradation of nucleic acid, we used a primerset and probe
directed against the human U1 small nuclear ribonucleoprotein
(snRNP)-specific A protein (U1A mRNA) (Compton, 1991;
Nelissen et al, 1991). All samples were run in duplicate on
separate microplate readers (Lambda FL-600, Bio-Tek Instru-
ments, Winooski, USA). RNA isolated from CaSki/SiHa or HeLa
cells served as positive controls for HPV 16 and HPV 18
transcripts, respectively. For the other HPV types, these cell lines
were used as negative controls. In addition, negative controls
consisting of all reagents except RNA were included for every
seventh reaction.
Human papillomavirus DNA analysis: polymerase
chain reaction
The same nucleic acid extracts and amounts as used in the NASBA
reaction were used for HPV DNA PCR. The L1 consensus primers
Gp5þ/Gp6þ (Roda Husman et al, 1995) were used to assess the
samples that contained HPV DNA. The PCR amplification was
carried out in a volume of 50ml containing as final concentrations
75mM Tris-HCl (pH 8.8), 0.01% Tween, 20mM (NH4)2SO4, 1.5mM
MgCl2, 0.2mM dNTPs, 50pmol of Gp5þ and Gp6þ primers, and
1.0U of Taq DNA polymerase (Sigma-Aldrich, Missouri, USA).
Human papillomavirus DNA was amplified by using a thermo
cycler heat block from MWG, Ebersberg, Germany (Primus 96 HPL
Table 1 Cytology and histology results
Cytology Histology 1 (Biopsy 1) Histology 2a Histology 2b (Biopsy 2) Histology 3
Squamous cell carcinoma 2
Adenocarcinoma 1
CIN III 152 151 53 37 158
CIN II 28 17 30 30 13
CIN I 3 6 32 14 6
HPV/condyloma/koilocytosis 4 7
Uncertain benign/malignant
a 3 1
Benign with control
b 21 1 2
Normal 71 11 7
Inadequate 2 3 3
Not representative for transformation zone 88
Uncertain diagnosis 2
Total 190 190 190 190 190
aCorresponding to Bethesda nomenclature ASC-H.
bCorresponding to Bethesda nomenclature ASC-US.
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941C, followed by 40 cycles of denaturation for 1min at 941C,
annealing for 2min at 401C, and extension for 1.5min at 721C,
prior to a final extension for 4min at 721C. Genotyping of HPV
was performed by using PCR type-specific primers against HPV
types 16, 18, 31, 33, 45, 52, and 58 (NorChip, Klokkarstua,
Norway), utilising 25pmol of each primer. The PCR conditions
were 35 cycles of denaturation for 0.5min at 941C, annealing
0.5min at 571C, and extension for 1min at 721C. For a cellular
control, we used primers against the human b-globin gene
(Mwenda et al, 1999). DNA isolated from CaSki/SiHa or HeLa
cells served as positive controls for HPV 16 and HPV 18,
respectively. For the other HPV types, these cell lines were used
as negative controls. Negative controls, consisting of all reagents
except DNA, were included for every seventh reaction. Fragments
were visualised by using the 2100 Bioanalyzer Multi-Instrument
system (Agilent Technologies, CA, USA).
DNA sequencing
Samples that tested HPV DNA positive with the consensus primers
yet negative with type-specific PCR primers were sequenced in
order to determine the HPV type. Sequencing was performed at the
University of Oslo (Norway) by the MegaBACE Sequence Analyzer
(Amersham Biosciences, Little Chalfont, England) according to
in-house protocols. Sequence comparisons were performed using
BLAST.
RESULTS
Cytology and histology
Table 1 summarises the clinical diagnoses of patients included in
the study. According to cytology, 180 out of 190 patients had
indications of high-grade dysplasia (CIN II or III); eight had
repeatedly the diagnosis of mild or low-grade abnormalities, and
two patients had an equivocal cytological smear. In all cases, the
cytological report was the basis for subsequent hospital admit-
tance, colposcopy and biopsy (Histology 1, Table 1). A high-grade
lesion (CIN II or III) was in 168 out of 190 cases confirmed by
histological examination. All patients having a high-grade lesion
either at cytology or histology were admitted for conisation. In
addition, some patients were admitted for conisation on the basis
of equivocal cytology and histology. Biopsy 2, taken at conisation
(Histology 2b, Table 1), was used for RNA analysis. Only one
biopsy was taken, and because local anaesthesia made it difficult to
locate the lesion by colposcopy, this biopsy was not always
representative for an existing CIN lesion that was later revealed in
the cone. This biopsy was examined twice by a pathologist who
was blinded to the subject’s HPV status. The first histological
examination (Histology 2a, see Table 1) diagnosed only 83 samples
of the original 168 as CIN II/III, 32 as CIN I, and four as HPV/
condyloma. In 71 samples, high-grade lesions were not detected.
Re-examination of the slide, to check for representativeness
(Histology 2b), revealed 88 of the biopsies as not representative,
that is, the tissue was not taken from the transformation zone; CIN
III was found in 37 cases, CIN II in 30 cases, and CIN I in 14 cases.
Conisation confirmed 158 of the women to harbour a CIN III
lesion, 13 having CIN II. As many as 19 women had a low-grade or
equivocal diagnosis at conisation (Table 1): six were diagnosed as
CIN I, three as nonrepresentative, and 10 were diagnosed as benign
or normal. Almost all of these women were given a high-grade
diagnosis at cytology, but were given a low-grade/benign diagnosis
at the first histological examination (Histology 1); four of these 19
women were found to be HPV positive (Table 2).
Human papillomavirus RNA and DNA in CIN
Human papillomavirus E6/E7 transcripts from HPV 16, 18, 31, 33,
45, 52, and 58 were detected in 88 out of 190 (46%) biopsies, of
which 83 out of 88 (94%) represented HPV 16, 18, 31, 33, and 45.
Of the 37 samples diagnosed as CIN III (Histology 2b) 34 cases
(92%) showed E6/E7 expression, only representing HPV 16, 18, 31,
33, and 45. In addition, we found oncogenic expression in 16 out of
30 cases (53%) with CIN II. No CIN I cases (n¼14) were found to
contain HPV RNA. Transcripts were also found in two out of seven
cases of borderline samples, in two out of 11 cases not showing
dysplasia, and in three samples being histologically inadequate.
Among the 88 nonrepresentative samples, we detected HPV RNA
in 31 samples (35%). Results are presented in Figure 1. Figure 2
shows a typical RNA amplification curve as measured by real-time
NASBA, exemplified by an HPV 16-positive sample.
In order to investigate the prevalence of HPV DNA vs RNA in
the cervical biopsies, and to evaluate the analytical specificity and
Table 2 Samples diagnosed as normal or borderline at conisation (Histology 3), including previous cytological and histological diagnoses, as well as
NASBA and PCR results
Cytology Histology 1 (Biopsy 1) Histology 2a Histology 2b (Biopsy 2) Histology 3 NASBA PCR Gp5+6+
CIN III Benign with control Normal Nonrepresentative Normal – – –
CIN III Benign with control Normal Normal Normal – – –
CIN III Benign with control CIN I Nonrepresentative Normal – – –
CIN III Benign with control CIN I Nonrepresentative Normal – – –
CIN III Benign with control CIN I Nonrepresentative Normal 31 31 +
CIN II Benign with control Normal Nonrepresentative Normal – – –
CIN III Benign with control CIN I Nonrepresentative Normal – – –
CIN III Inadequate CIN I CIN I Inadequate – – –
Uncertain benign Inadequate Normal Nonrepresentative Inadequate – – –
Uncertain benign CIN III Normal Normal Inadequate – – –
CIN III Benign with control Normal Nonrepresentative Benign with control – – –
CIN III Benign with control CIN I HPV Benign with control – – +
a
CIN II Benign with control Normal Nonrepresentative Uncertain benign 16 16 +
CIN II CIN I Normal Nonrepresentative CIN I – – –
CIN I CIN I CIN II Koilocytosis CIN I – – –
CIN III CIN I CIN I Nonrepresentative CIN I – – –
CIN III CIN I CIN I Nonrepresentative CIN I – – –
CIN III CIN I Normal Normal CIN I 16 16 +
CIN III CIN I Normal Normal CIN I – – –
aBy sequencing revealed as HPV 35; –negative test result; Non-representative¼not representative for the transformation zone.
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same 190 biopsies, both by type-specific and consensus PCR.
Results are summarised in Table 3. Type-specific PCR, directed
against E6/E7 for the HPV types 16, 18, 31, 33, 45, 52, and 58,
detected 90 samples containing HPV, of which all but two were
positive by NASBA. Using the consensus Gp5þ/Gp6þ primers
directed against the L1 gene, PCR detected HPV in 85 out of 190
biopsies, of which five were not detected by type-specific PCR. In
addition, 10 samples that were positive by type-specific PCR were
not detected by using consensus primers. In total, taking both
consensus and type-specific PCR into account, PCR found 95
samples HPV positive.
The expression pattern for the different HPV types according to
CIN grade is summarised in Table 4. Human papillomavirus 16
was the most common type found (50 out of 88), followed by HPV
31 (14 out of 88), HPV 33 (nine out of 88), HPV 18 (seven out of
88), HPV 45 (seven out of 88), HPV 52 (three out of 88), and HPV
58 (three out of 88). Five patients had multiple infections, all with a
high-grade CIN diagnosis (CIN II or III): one patient had mixed
expression of HPV 16 and HPV 18, one of HPV 16 and HPV 31,
two of HPV 16 and HPV 33, and one of HPV 33 and HPV 58. HPV
52 and 58 were not detected in any CIN III cases. Table 5 shows the
distribution of HPV types for different age groups.
DNA sequencing
The five samples positive by consensus PCR, yet negative by type-
specific PCR and NASBA, were typed by sequencing. Three
samples were revealed as HPV 35 (one CIN III, one borderline, one
nonrepresentative), one sample as HPV 51 (nonrepresentative),
and one sample as HPV 67 (CIN II).
DISCUSSION
To our knowledge, this is the first study performing HPV mRNA
analysis for several HPV types on a large number of histologically
confirmed lesions. By comparing the RNA technology NASBA
with conventional PCR of HPV DNA, this study permitted us
to evaluate HPVs oncogenic activity in different grades of
dysplasia. With a few exceptions, all patients included in the
study were originally given a high-grade CIN diagnosis (CIN II/III)
by cytological examination and/or by the first histological
examination (Biopsy 1). However, the RNA analysis was
performed on a separate biopsy (Biopsy 2), taken from the
ectocervix/transformation zone at conisation. Only one biopsy
was taken, and because local anaesthesia made it difficult to
locate the lesion by colposcopy, this biopsy was not always
representative for an existing CIN II/III lesion that was later
revealed in the cone.
Biopsy 2 was examined twice histologically, in order to grade
any dysplasia and to define samples not representative for the
transformation zone, that is, samples containing only tissue from
portio, external to the os (Histology 2a vs 2b, Table 1). The
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Figure 1 Oncogenic HPV activity detected by real-time NASBA. The
presence of HPV DNA and RNA increased with the histological severity of
the cervical intraepithelial neoplasia (CIN). HPV was also detected in
samples with histological diagnosis normal, borderline, or nonrepresenta-
tive. The respective values in percentage are indicated above each bar.
Borderline samples include HPV, condyloma, and koilocytosis.
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Figure 2 Amplification of HPV RNA by real-time NASBA. A positive
reaction result is revealed as a sigmoid curve.
Table 3 NASBA results shown according to PCR positives and negatives (both consensus and type-specific), for each of the histological categories
Histology 2b
PCR positives (n¼95) PCR negatives (n¼95)
No. of NASBA positives No. of NASBA negatives No. of NASBA positives No. of NASBA negatives
CIN III (n¼37) 34 2
a 01
CIN II (n¼30) 16 1
b 01 3
CIN I (n¼14) 0 1
c 01 3
Borderline
d (n¼7) 2 1
e 04
Normal (n¼11) 2 0 0 9
Inadequate (n¼3) 3 0 0 0
Nonrepresentative (n¼88) 31 2
f 05 5
Total (n¼190) 88 7 0 95
Non-representative¼not representative for the transformation zone.
aHPV16+HPV35.
bHPV67.
cHPV16.
dBorderline samples include HPV, condyloma, and koilocytosis.
eHPV35.
fHPV35+HPV51.
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ymajority of the biopsies showing discrepancies in Histology 2a vs
2b presents small areas of metaplastic atypia, difficult to fit into the
CIN groups (Geng et al, 1999; Montes et al, 1999; Ng et al, 2002;
Zuna et al, 2002). The discrepancy in the relative frequency of
‘normals’ between Histology 2a and 2b is due to the fact that in
2b the emphasis was on representativeness for the transforma-
tion zone.
In the NASBA reaction, as well as in the type-specific PCR, we
tested for the reportedly most common oncogenic HPV types 16,
18, 31, 33, 45, 52, and 58 (Walboomers et al, 1999; Munoz et al,
2003). We revealed that all but two PCR-positive cases also showed
E6/E7 transcription. This shows that, at the level of severe
dysplasia, HPV exerts an oncogenic activity (Nakagawa et al,
2000). Of the 37 samples diagnosed as CIN III (Histology 2b), we
found 34 cases (92%) HPV RNA positive; three out of 37 CIN III
cases did not show any oncogenic expression, one being PCR HPV
16 positive (Table 3). This sample may represent cell abnormalities
prone to regression, as a consequence of HPV expression being
switched off: regression of abnormal cytology in women with a
positive HPV test at baseline is often associated with viral
clearance (Nobbenhuis et al, 2001). This is, however, a field not
widely explored and much remains to be learned about the
mechanisms behind regression of cervical dysplasia. Furthermore,
we see a clear increase in the incidence of HPV, both DNA and
RNA, with the severity of the lesion (Figure 1), which is in
accordance with previous studies (Sotlar et al, 1998; Nakagawa
et al, 2000). The finding that no CIN I cases demonstrated HPV
oncogenic expression suggests that, even in the presence of
concominant CIN III in other areas, histologically defined CIN I
may not be strictly related to HPV and precancerous disease
(Crum et al, 1999). However, further studies are needed in order to
confirm this assumption.
Human papillomavirus expression was not restricted to the CIN
lesions. We also found oncogenic expression in two of 11 cases not
showing dysplasia (Histology 2b, Table 1). In general, this may
indicate a potential risk for the development of a high-grade lesion.
In these cases, however, our finding most likely reflects the lesion
confirmed by Histology 1, located in another part of the cervix.
This indicates that the virus can be present in the cervix exerting
an oncogenic activity before cell changes can be visualised
histologically, supporting the view that the natural history of
HPV includes periods before the manifestation of a cell
abnormality (Moscicki et al, 1998; Nobbenhuis et al, 2001). Also
among biopsies not representative for the transformation zone, as
well as in inadequate samples, we detected a high rate of HPV DNA
and RNA positivity (Figure 1).
In addition to type-specific PCR, we also tested the biopsies
for HPV DNA using HPV consensus primers (Table 3). We made
use of the primer set Gp5þ/Gp6þ, which detected all but 10
of the samples found positive by type-specific PCR. The ‘missed’
cases may be attributed to the fact that consensus primers are
not sufficiently sensitive to detect all cases of HPV infection, at
least not the cases containing a low HPV copy number (Karlsen
et al, 1996). Besides, the use of these consensus primers may
leave some important oncogenic HPV types undetected because
of loss of the L1 sequence during viral integration. In clinical
practice this can be critical, since integrated HPV 16/18 DNA has
been revealed in various stages of dysplasia (Nagao et al, 2002;
Gallo et al, 2003) and is shown to be common in patients with
cervical carcinomas (Park et al, 1997; Kalantari et al, 1998;
Walboomers et al, 1999). Therefore, the use of type-specific PCR,
directed against one of the early-region genes (preferentially E6
and E7), is always recommended. On the other hand, consensus
PCR detected five cases not detected by type-specific PCR. These
samples were by sequencing revealed as HPV 35, 51, and 67.
Nevertheless, the high association between consensus and type-
specific PCR/NASBA supports that the HPV types included in this
study are the most common types present in cervical dysplasia
(Bosch et al, 2002).
The problem of inter- and intraobserver variability in cytology
and histopathology paves the way for additional objective
strategies in detecting cervical cancer precursors. Moreover,
current management protocols may in certain cases lead to
overtreatment (Meijer et al, 1998). This problem is emphasised in
the present study: at the final evaluation of the cone, as many as 19
of the women received either a normal, benign, or low-grade
diagnosis at (Histologi 3, Table 2). Almost all of these women had a
high-grade diagnosis at cytology, yet a low-grade diagnosis at the
Table 4 Distribution of different HPV types detected by NASBA
HPV types
HPV 16 HPV 18 HPV 31 HPV 33 HPV 45 HPV 52 HPV 58
CIN III 25 3 4 3 2
CIN II 8 1 2 4 1 1 1
Borderline 1 1
Normal 1 1
Inadequate 2 1
Nonrepresentative 13 3 8 2 4 1
Total (n¼88) 50 7 14 9 7 3 3
Distribution of the seven high-risk HPV types determined by NASBA in the biopsies taken at conisation (Histology 2b). The total number is summarised to 93 due to multiple
infections in five cases. Nonrepresentative¼not representative for the transformation zone.
Table 5 Distribution of high-risk HPV RNA for the age groups indicated
Year of birth
No. of women
(n¼190) HPV 16 HPV 18 HPV 31 HPV 33 HPV 45 HPV 52 HPV 58
1926–1949 23 7 200001
1950–1959 32 8 111202
1960–1969 70 20 244330
1970–1979 65 15 294200
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was performed on the basis of high-grade cytological diagnoses,
assuming the histology as being nonrepresentative. Only four of
these women were found HPV positive, although we have to take
into account that 12 out of 19 biopsies on which the HPV analysis
were performed, were found to be nonrepresentative for the
transformation zone. Nevertheless, unnecessary conisations can
possibly be reduced by introducing HPV testing into the routine
assessment. This is especially important among young women,
who plan for future pregnancy, and for whom conisation entails
increased risk for premature birth.
In conclusion, this study shows that HPV DNA and RNA
detection achieve a similar result in biopsies of severe dysplasia,
strengthening the case that HPV E6/E7 gene expression is
necessary for oncogenesis in this region (zur Hausen, 1989). In
general, detection of HPV E6/E7 transcripts, in combination
with HPV typing, may have significant potential in identifying
women who may be at a heightened risk for developing cervical
dysplasia. However, our study unfortunately does not lend itself to
calculations of clinical sensitivity and specificity, because of
patient material selection and the fact that a relatively low number
of true cytological and histological negative cases were included in
the study. Therefore, RNA-based strategies for HPV testing are
currently being investigated both in a screening context and in
longitudinal follow-up studies.
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